HUMANIGEN, INC | Business Contracts

Settlement Agreement dated as of December 16, 2022, by and between the Registrant and Catalent Pharma Solutions, LLC (Filed With SEC on March 30, 2023)

Description of Registrants Director Compensation Policy (Filed With SEC on March 30, 2023)

Loan and Security Agreement, dated March 10, 2021, by and between the Registrant and Hercules Capital, Inc (Filed With SEC on May 13, 2021)

INDEMNITY AGREEMENT (Filed With SEC on March 10, 2021)

License Agreement, dated as of November 3, 2020, by and among the Registrant, KPM Tech Co., Ltd and Telcon RF Pharmaceutical, Inc (Filed With SEC on March 10, 2021)

Employment Agreement, dated as of April 21, 2021, by and between Humanigen, Inc. and Dr. Adrian Kilcoyne (Filed With SEC on April 12, 2022)

Description of Registrants Director Compensation Policy (Filed With SEC on March 1, 2022)

Form of Non-qualified Stock Option Award Agreement under 2020 Omnibus Incentive Plan (Filed With SEC on August 12, 2021)

Form of Incentive Stock Option Award Agreement under 2020 Omnibus Incentive Plan (Filed With SEC on August 12, 2021)

Underwriting Agreement, dated March 30, 2021, by and among the Company, Jefferies LLC, Credit Suisse Securities (USA) LLC and Cantor Fitzgerald & Co., as representatives of the... (Filed With SEC on April 2, 2021)

Consulting Agreement, dated as of March 6, 2021, by and between the Registrant and David Tousley (Filed With SEC on March 10, 2021)

Amended and Restated Cooperative Research and Development Agreement, dated as of January 21, 2021, by and among the Registrant, Joint Program Executive Office for Chemical,... (Filed With SEC on March 10, 2021)

Amended and Restated Employment Agreement, dated as of September 24, 2020, by and between the Registrant and Dr. Dale Chappell (Filed With SEC on March 10, 2021)

Employment Agreement, dated as of July 6, 2020, by and between the Registrant and David Tousley (Filed With SEC on March 10, 2021)

Employment Agreement dated as of August 1, 2020, by and between the Registrant and Timothy Morris (Filed With SEC on March 10, 2021)

Amended and Restated Employment Agreement, dated as of October 29, 2020, by and between the Registrant and Dr. Cameron Durrant (Filed With SEC on March 10, 2021)

Description of Securities (Filed With SEC on March 10, 2021)

Master Services Agreement effective as of January 8, 2021 between Humanigen, Inc. and EVERSANA Life Science Services, LLC (Filed With SEC on January 14, 2021)

Controlled Equity OfferingSM Sales Agreement, dated December 31, 2020, by and between the Company and Cantor Fitzgerald & Co (Filed With SEC on December 31, 2020)

Underwriting Agreement, dated September 17, 2020, by and among the Company, J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several underwriters (Filed With SEC on September 21, 2020)

Form of Non-qualified Stock Option Award Agreement (Filed With SEC on September 11, 2020)

Form of Incentive Stock Option Award Agreement (Filed With SEC on September 11, 2020)

Humanigen, Inc. 2020 Omnibus Incentive Compensation Plan, effective September 11, 2020 (Filed With SEC on September 11, 2020)

Form of Humanigen, Inc. 2020 Omnibus Incentive Compensation Plan (Filed With SEC on August 3, 2020)

Clinical Trial Agreement, dated as of July 24, 2020, by and between Humanigen, Inc. and The National Institute of Allergy and Infectious Diseases (NIAID), part of the National... (Filed With SEC on July 30, 2020)

Securities Purchase Agreement, dated as of June 1, 2020, by and among Humanigen, Inc. and the investors party thereto (Filed With SEC on June 15, 2020)

Form of March 2020 Convertible Redeemable Promissory Notes dated March 13, 2020 and March 19, 2020 (Filed With SEC on May 15, 2020)

Form of Amendment Number 3, dated March 20, 2020, to the Secured Bridge Note, dated June 28, 2019 (Filed With SEC on March 23, 2020)

Form of Amendment Number 2, dated March 20, 2020, to the Secured Bridge Note, dated November 12, 2019 (Filed With SEC on March 23, 2020)

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 (Filed With SEC on March 16, 2020)

Form of Amendment Number 2, dated December 30, 2019, to the Secured Bridge Note, dated June 28, 2019 and as amended on October 8, 2019 (Filed With SEC on December 31, 2019)

Registration Rights Agreement, dated as of November 8, 2019, by and between Humanigen, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on November 12, 2019)

Purchase Agreement, dated as of November 8, 2019 by and between Humanigen, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on November 12, 2019)

Form of Amendment Number 1, dated October 8, 2019, to the Secured Bridge Note, dated June 28, 2019 (Filed With SEC on October 8, 2019)

Clinical Collaboration Agreement, dated May 30, 2019 between the Registrant and Kite Pharma, Inc (Filed With SEC on August 13, 2019)

Form of 2019 Bridge Note (Filed With SEC on August 13, 2019)

Form of 2019 Convertible Note (Filed With SEC on August 13, 2019)

Form of Convertible Note (Filed With SEC on November 6, 2018)

Amended Employment Agreement dated August 22, 2018, between the Company and Jon. G. Jester (Filed With SEC on November 6, 2018)

Form of Advance Note (Filed With SEC on August 9, 2018)

HUMANIGEN, INC (40)